Roche shares drop as oral breast cancer drug fails in trial

FRANKFURT, March 9 (Reuters) - Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

Roche Breast-Cancer Drug Combination Misses Main Target in Trial

A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

Bristol's cancer drug meets main goal in late-stage trial

March 9 (Reuters) - Bristol Myers Squibb on Monday said its experimental cancer drug met the main goal of a late-stage study.

Study finds no evidence that prostate cancer drugs interact with anticoagulants to increase bleeding, clotting risks

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
BioSpace

Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
STAT

A setback for Roche’s breast cancer drug

Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news ...
BioSpace

Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies

Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated ...
News-Medical.Net on MSN

Taking anticoagulants alongside prostate cancer drugs does not increase bleeding risk

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Roche shares drop as oral breast cancer drug trial misses goal

Roche said the late-stage trial did not provide reliable evidence that ​the drug's use in combination with Pfizer's Ibrance ...